4583.T
Chiome Bioscience Inc.
4583.T
()103,00 JPY
-71.93% ROA
-95.61% ROE
-5.23x PER
6.611.938.528,00 JPY
27.29% DER
0% Yield
-190.76% NPM
Chiome Bioscience Inc. Stock Analysis
Chiome Bioscience Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|
Chiome Bioscience Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|
Chiome Bioscience Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2019 | 447.576.000 | |
| 2020 | 480.853.000 | 6.92% |
| 2021 | 712.932.000 | 32.55% |
| 2022 | 630.815.000 | -13.02% |
| 2023 | 682.464.000 | 7.57% |
| 2024 | 536.336.000 | -27.25% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2019 | 1.299.069.000 | |
| 2020 | 1.156.582.000 | -12.32% |
| 2021 | 1.312.188.000 | 11.86% |
| 2022 | 1.135.613.000 | -15.55% |
| 2023 | 1.051.904.000 | -7.96% |
| 2024 | 801.648.000 | -31.22% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2019 | 0 | |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2019 | -1.397.096.000 | |
| 2020 | -1.286.935.000 | -8.56% |
| 2021 | -1.325.040.000 | 2.88% |
| 2022 | -1.241.039.000 | -6.77% |
| 2023 | -1.213.968.000 | -2.23% |
| 2024 | -1.034.752.000 | -17.32% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2019 | 284.647.000 | |
| 2020 | 245.271.000 | -16.05% |
| 2021 | 422.458.000 | 41.94% |
| 2022 | 348.858.000 | -21.1% |
| 2023 | 398.595.000 | 12.48% |
| 2024 | 311.036.000 | -28.15% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2019 | -1.403.821.000 | |
| 2020 | -1.293.798.000 | -8.5% |
| 2021 | -1.479.895.000 | 12.58% |
| 2022 | -1.242.871.000 | -19.07% |
| 2023 | -1.220.018.000 | -1.87% |
| 2024 | -1.039.736.000 | -17.34% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2019 | -45 | |
| 2020 | -36 | -22.22% |
| 2021 | -37 | 0% |
| 2022 | -28 | -28.57% |
| 2023 | -25 | -16.67% |
| 2024 | -18 | -33.33% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2019 | -1.537.360.000 | |
| 2020 | -1.360.143.000 | -13.03% |
| 2021 | -1.131.291.000 | -20.23% |
| 2022 | -1.191.009.000 | 5.01% |
| 2023 | -1.069.192.000 | -11.39% |
| 2024 | 0 | 0% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2019 | -1.537.360.000 | |
| 2020 | -1.360.143.000 | -13.03% |
| 2021 | -1.131.291.000 | -20.23% |
| 2022 | -1.191.009.000 | 5.01% |
| 2023 | -1.069.192.000 | -11.39% |
| 2024 | 0 | 0% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2019 | 0 | |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2019 | 2.621.508.000 | |
| 2020 | 3.109.967.000 | 15.71% |
| 2021 | 1.893.048.000 | -64.28% |
| 2022 | 1.790.746.000 | -5.71% |
| 2023 | 1.157.723.000 | -54.68% |
| 2024 | 1.070.531.000 | -8.14% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2019 | 2.808.090.000 | |
| 2020 | 3.494.554.000 | 19.64% |
| 2021 | 2.339.439.000 | -49.38% |
| 2022 | 2.215.470.000 | -5.6% |
| 2023 | 1.751.454.000 | -26.49% |
| 2024 | 1.557.439.000 | -12.46% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2019 | 145.133.000 | |
| 2020 | 384.587.000 | 62.26% |
| 2021 | 446.391.000 | 13.85% |
| 2022 | 424.724.000 | -5.1% |
| 2023 | 593.731.000 | 28.47% |
| 2024 | 486.907.000 | -21.94% |
Chiome Bioscience Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 10.42
- Net Income per Share
- -19.87
- Price to Earning Ratio
- -5.23x
- Price To Sales Ratio
- 11.26x
- POCF Ratio
- 0
- PFCF Ratio
- 0
- Price to Book Ratio
- 5.48
- EV to Sales
- 9.88
- EV Over EBITDA
- -5.2
- EV to Operating CashFlow
- 0
- EV to FreeCashFlow
- 0
- Earnings Yield
- -0.19
- FreeCashFlow Yield
- 0
- Market Cap
- 6,61 Bil.
- Enterprise Value
- 5,80 Bil.
- Graham Number
- 92.14
- Graham NetNet
- 12.28
Income Statement Metrics
- Net Income per Share
- -19.87
- Income Quality
- 0
- ROE
- -0.96
- Return On Assets
- -0.72
- Return On Capital Employed
- -1
- Net Income per EBT
- 1
- EBT Per Ebit
- 0.99
- Ebit per Revenue
- -1.92
- Effective Tax Rate
- -0
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 1.53
- Stock Based Compensation to Revenue
- -0
- Gross Profit Margin
- 0.55
- Operating Profit Margin
- -1.92
- Pretax Profit Margin
- -1.9
- Net Profit Margin
- -1.91
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- 0
- Free CashFlow per Share
- 0
- Capex to Operating CashFlow
- 0
- Capex to Revenue
- 0
- Capex to Depreciation
- 0
- Return on Invested Capital
- -0.83
- Return on Tangible Assets
- -0.72
- Days Sales Outstanding
- 41.03
- Days Payables Outstanding
- 31.98
- Days of Inventory on Hand
- 72.89
- Receivables Turnover
- 8.9
- Payables Turnover
- 11.41
- Inventory Turnover
- 5.01
- Capex per Share
- 0
Balance Sheet
- Cash per Share
- 19,58
- Book Value per Share
- 18,99
- Tangible Book Value per Share
- 18.99
- Shareholders Equity per Share
- 18.99
- Interest Debt per Share
- 5.22
- Debt to Equity
- 0.27
- Debt to Assets
- 0.19
- Net Debt to EBITDA
- 0.73
- Current Ratio
- 3.29
- Tangible Asset Value
- 1,07 Bil.
- Net Current Asset Value
- 0,93 Bil.
- Invested Capital
- 989983000
- Working Capital
- 0,99 Bil.
- Intangibles to Total Assets
- 0
- Average Receivables
- 0,12 Bil.
- Average Payables
- 0,03 Bil.
- Average Inventory
- 55724000
- Debt to Market Cap
- 0.04
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Chiome Bioscience Inc. Profile
About Chiome Bioscience Inc.
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer which is under phase 1 trial; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma which is under phase 1 trial; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and breast cancer (TNBC) which is under phase 1 trial. The company's product pipeline under preclinical study includes LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases; PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, triple negative breast cancer; and PFKR, anti-CX3CR1 antibody for secondary progressive multiple sclerosis. It serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
- CEO
- Mr. Shigeru Kobayashi M.E.
- Employee
- 0
- Address
-
Sumitomo Fudosan Nishi-shinjuku Bldg.No.6
Tokyo, 151-0071
Chiome Bioscience Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Ms. Teruyo Taoka M.B.A., M.S. GM of Development Division & Director |
70 |
| 2 |
Mr. Ryuji Osawa Ph.D. Head of Business Development and Executive Officer |
70 |
| 3 |
Mr. Shigeru Kobayashi M.E. Chief Executive Officer, President & Executive Director |
70 |
| 4 |
Mr. Arihiko Bijohira Chief Financial Officer, Head of Corporate Planning Officer & Executive Director |
70 |
| 5 |
Dr. Masamichi Koike Ph.D. Head of Research Division & Executive Director |
70 |